Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy

Dorit Verhoeven, Arie Jan Stoppelenburg, Friederike Meyer-Wentrup, Marianne Boes

Research output: Contribution to journalReview articlepeer-review

Abstract

Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.

Original languageEnglish
Pages (from-to)22-31
Number of pages10
JournalClinical Immunology
Volume190
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

Dive into the research topics of 'Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy'. Together they form a unique fingerprint.

Cite this